Pfizer has added an acquisition pact to its latest string of deals. The pharma giant said today that it is buying out Redvax, a subsidiary of Switzerland's Redbiotec, in order to get its hands on a preclinical cytomegalovirus (CMV) vaccine candidate.
Fujifilm has completed its acquisition of Kalon Biotherapeutics, a contract manufacturer with a focus on vaccines.
Eli Lilly started the new year by announcing it has closed its $5.4 billion acquisition of Novartis Animal Health, in the process expanding its Elanco animal health unit to 17 manufacturing sites and 14 R&D centers.
Bloomberg reports that Stryker is planning to offer a premium for the U.K.'s S&N of about 30%. Currently, the target has a valuation of about $16.3 billion. The sources say a tax inversion is not planned. However, one of the unnamed sources also says Stryker's management could change its mind.
It's been a wild ride through the M&A world for pharma this year, and analysts predict that may just continue into 2015. Companies have been wheeling and dealing at breakneck pace, with more than a couple inking multiple pacts. But plenty of drugmakers are still in search of a deal that will move the needle.
2014 was the year for medical device M&A activity. We don't expect to see med tech merger mania slow anytime soon, as the underlying motivations to improve growth rates, save on taxes and buy into new technology haven't changed. But there just aren't very many big medical device companies and that in itself limits the deal potential going forward.
In one interview published over the weekend, AstraZeneca CEO Pascal Soriot pooh-poohed the idea of Pfizer coming back with another takeover bid. In another, he gave a subtle warning about his company's stated goal of hitting $45 billion in sales within a decade.
Roche snatched up DNA sequencing outfit Bina Technologies for an undisclosed sum, continuing its M&A winning streak and expanding its diagnostics footprint.
Contract researcher KCR is dialing up its presence in Ukraine, buying out a competitor's whole clinical portfolio and doubling down on a country it believes is ripe for R&D growth.
Just one month after announcing a $66 billion pact to buy Allergan, Actavis is eyeing Spain's Almirall as a way to boost its European growth, according to Bloomberg.